Structure-based methods for the prediction of drug metabolism

• DUFFY JC: Prediction of pharmacokinetic parameters in drug design and toxicology. In: Predicting Chemical Toxicity and Fate. MTD Cronin, DJ Livingstone (Eds), CRC Press, Boca Raton, FL, USA (2004):229-261.
   Google Scholar
• EKINS S, WALLER CL, SWAAN PW, CRUCIANI G, WRIGHTON SA, WIKELJH: Progress in predicting ADME parameters in silico. J. Pharmacol. Toxicol. Methods (2000) 44:251-272.
   PubMed Web of Science ®Google Scholar
• VAN DE WATERBEEMD H: High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr. Opin Drug Disc. Devel. (2002) 5:33-43.
   PubMed Web of Science ®Google Scholar
• TURNER JV, MADDALENA DJ, CUTLER DJ: Pharmacokinetic parameter prediction from drug structure using artificial neural networks. Int. J. Pharmacol. (2004) 270:209-219.
   Google Scholar
• DE GRAAF C, VERMEULEN NPE, FEENSTRA KA: Cytochrome P450 insilico: an integrative modeling approach. J. Med. Chem. (2005) 48:2725-2755.
   PubMed Web of Science ®Google Scholar
• DE GROOT MJ, EKINS S: Pharmacophore modeling of cytochromes P450. Adv. Drug Del. Rev. (2002) 54:367-383.
   PubMed Web of Science ®Google Scholar
• DE GROOT MJ, KIRTON SB, SUTCLIFFE MJ: In silico methods for predicting ligand binding determinants of cytochromes P450. Curr. Topics Med. Chem. (2004) 4:1803-1824.
   PubMed Web of Science ®Google Scholar
• EKINS S, BOULANGER B, SWAAN PW, HUPCEY MAZ: Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J. Comput. Aided Mol. Des. (2002) 16:381-401.
   PubMed Web of Science ®Google Scholar
• EKINS S: In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem. Soc. Trans. (2003) 31:611-614.
   PubMed Web of Science ®Google Scholar
• HANSCH C, LEO A, MEKAPATI SB, KURUP A: QSAR and ADME. Bioorg. Med. Chem. (2004) 12:3391-3400.
   PubMed Web of Science ®Google Scholar
• HANSCH C, MEKAPATI SB, KURUP A, VERMA RP: QSAR of cytochrome P450. Drug Metab. Rev. (2004) 36:105-156.
   PubMed Web of Science ®Google Scholar
• KULKARNI SA, ZHU J, BLECHINGERS: In silico techniques for the study and prediction of xenobiotic metabolism: a review. Xenobiotica (2005) 35:955-973.
   PubMed Web of Science ®Google Scholar
• LANGOWSKI J, LONG A: Computer systems for the prediction of xenobiotic metabolism. Adv. Drug Del. Rev. (2002) 54:407-415.
   PubMed Web of Science ®Google Scholar
• LEWIS DFV: Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450CYP2 family enzymes. Toxicol. InVitro (2004) 18:89-97.
   PubMed Web of Science ®Google Scholar
• LONG A, WALKER JD: Quantitative structureactivity relationships for predicting metabolism and modeling cytochrome P450 enzyme activities. Environ. Toxicol. Chem. (2003) 22:1894-1899.
   PubMed Web of Science ®Google Scholar
• MANKOWSKI DC, EKINS S: Prediction of human drug metabolizing enzyme induction. Curr. Drug Metab. (2003) 4:381-391.
   PubMed Web of Science ®Google Scholar
• NORINDER U: In silico modelling of ADMET a minireview of work from 2000 to 2004. SAR QSAR Environ. Res. (2005) 16:1-11.
   PubMed Web of Science ®Google Scholar
• PAYNE MP: Computer-based methods for the prediction of chemical metabolism and biotransformation within biological organisms. In: Predicting Chemical Toxicity and Fate. MTD Cronin, DJ Livingstone (Eds), CRC Press, Boca Raton, FL, USA (2004):205-227.
   Google Scholar
• RETTIE AE, JONES JP: Clinical and toxicological relevance of CYP2C9: drugdrug interactions and pharmacogenetics. Ann. Rev. Pharmacol. Toxicol. (2005) 45:477-494.
   PubMed Web of Science ®Google Scholar
• SIRAKI AG, CHEVALDINA T, MORIDANI MY, OBRIEN PJ: Quantitative structuretoxicity relationships by accelerated cytotoxicity mechanism screening. Curr. Opin. Drug Disc. Devel. (2004) 7:118-125.
   PubMed Web of Science ®Google Scholar
• SMITH PA, SORICH MJ, LOW LSC, MCKINNON RA, MINERS JO: Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. J. Mol. Graphics Mod. (2004) 22:507-517.
   PubMed Web of Science ®Google Scholar
• TESTA B, CRUCIANI G: Structuremetabolism relations and the challenge of predicting biotransformation. In: Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies. B Testa, H van de Waterbeemd, G Folkers, R Guy (Eds), Wiley-VCH, Weinheim, Germany (2001):65-84.
   Google Scholar
• VAN DE WATERBEEMD H, GIFFORDE: ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. (2003) 2:192-204.
   PubMed Web of Science ®Google Scholar
• FRANK R, HARGREAVES R: Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. (2003) 2:566-580.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA Y: Druggability: selecting optimised drug candidates. Drug Discov. Today (2005) 10:1577-1579.
   PubMed Web of Science ®Google Scholar
• POULIN P, KRISHNAN K: Molecular structure-based prediction of the toxicokinetics of inhaled vapors in humans. Int. J. Toxicol. (1999) 18:7-18.
   Web of Science ®Google Scholar
• CRONIN MTD: Toxicological information for use in predictive modeling: quality, sources and databases. In: Predictive Toxicology. C Helma (Ed.), Taylor & Francis, Boca Raton, FL, USA (2005):93-133.
   Google Scholar
• BORODINA Y, SADYM A, FILIMONOVD, BLINOVA V, DMITRIEV A, POROIKOV V: Predicting biotransformation potential from molecular structure. J. Chem. Inf. Comp. Sci. (2003) 43:1636-1646.
   PubMedGoogle Scholar
• KOROLEV D, BALAKIN KV, NIKOLSKY Y etal.: Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J. Med. Chem. (2003) 46:3631-3643.
   PubMed Web of Science ®Google Scholar
• MANGA N, DUFFY JC, ROWE PH, CRONIN MTD: A hierarchical QSAR model for urinary excretion of drugs in humans as a predictive tool for biotransformation. QSAR Comb. Sci. (2003) 22:263-273.
   Google Scholar
• LEWIS DFV: COMPACT: a structural approach to the modelling of cytochromes P450 and their interactions with xenobiotics. J. Chem. Technol. Biotechnol. (2001) 76:237-244.
   Web of Science ®Google Scholar
• GALLIANI G, RINDONE B, DAGNINOG, SALMONA M: Structurereactivity relationships in the microsomal oxidation of tertiary amines. Eur. J. Drug Metab. Pharmacokinet. (1984) 9:289-293.
   PubMed Web of Science ®Google Scholar
• NETZEVA TI, WORTH AP, ALDENBERG T etal.: Current status of methods for defining the applicability domain of (quantitative) structureactivity relationships. The report and recommendations of ECVAM Workshop 52. Altern. Lab. Anim. (2005) 33:155-173.
   PubMed Web of Science ®Google Scholar
• DURRER A, WALTHER B, RACCIATTIA, BOSS G, TESTA B: Structuremetabolism relationships in the hydrolysis of nicotinate esters by rat liver and brain subcellular fractions. Pharm. Res. (1991) 8:832-839.
   PubMed Web of Science ®Google Scholar
• LEWIS DFV, LAKE BG, DICKINS M: Quantitative structureactivity relationships (QSARs) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding. J. Enz. Inhib. Med. Chem. (2006) 21:127-132.
   PubMed Web of Science ®Google Scholar
• MULHOLLAND AJ: Modelling enzyme reaction mechanisms, specificity and catalysis. Drug Disc. Today (2005) 10:1393-1402.
   PubMed Web of Science ®Google Scholar
• GAO JL, TRUHLAR DG: Quantum mechanical methods for enzyme kinetics. Ann. Rev. Phys. Chem. (2002) 53:467-505.
   PubMed Web of Science ®Google Scholar
• IOANNIDES C, LEWIS DFV: Cytochromes P450 in the bioactivation of chemicals. Curr. Topics Med. Chem. (2004) 4:1767-1788.
   PubMed Web of Science ®Google Scholar
• BUCHWALD P, BODOR N: Quantitative structuremetabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of non-congener carboxylic esters. J. Med. Chem. (1999) 42:5160-5168.
   PubMed Web of Science ®Google Scholar
• LEWIS DFV: On the estimation of binding affinity (Gbind) for human P450 substrates. Curr. Drug Metab. (2003) 4:331-340.
   PubMed Web of Science ®Google Scholar
• LIVINGSTONE DJ: Building QSAR models: a practical guide. In: Predicting Chemical Toxicity and Fate. MTD Cronin, DJ Livingstone (Eds), CRC Press, Boca Raton, FL, USA (2004):151-170.
   Google Scholar
• HASHIDA M: In silico prediction of pharmacokinetic properties. Yakugaku Zassh J. Pharm. Soc. Japan (2005) 125:853-861.
   PubMed Web of Science ®Google Scholar
• SORICH MJ, MINERS JO, MCKINNON RA, WINKLER DA, BURDEN FR, SMITH PA: Comparison of linear and nonlinear classification algorithms for the prediction of drug and chemical metabolism by human UDP-glucuronosyltransferase isoforms. J. Chem. Inf. Comp. Sci. (2003) 43:2019-2024.
   PubMedGoogle Scholar
• KRIEGL JM, ARNHOLD T, BECK B, FOX T: Prediction of human cytochrome P450 inhibition using support vector machines. QSAR Comb. Sci. (2005) 24:491-502.
   Google Scholar
• YAP CW, CHEN YZ: Prediction of cytochrome P450 3A4, 2D6 and 2C9 inhibitors and substrates by using support vector machines. J. Chem. Inf. Model. (2005) 45:982-992.
   PubMed Web of Science ®Google Scholar
• SHEN M, XIAO YD, GOLBRAIKH A, GOMBAR VK, TROPSHA A: Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J. Med. Chem. (2003) 46:3013-3020.
   PubMed Web of Science ®Google Scholar
• BENDER A, GLEN RC: Molecular similarity: a key technique in molecular informatics. Org. Biomol. Chem. (2004) 2:3204-3218.
   PubMed Web of Science ®Google Scholar
• EKINS S, DE GROOT MJ, JONES JP: Pharmacophore and three-dimensional quantitative structureactivity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. (2001) 29:936-944.
   PubMed Web of Science ®Google Scholar
• EKINS S, BRAVI G, BINKLEY S etal.: Three- and four-dimensional-quantitative structureactivity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab. Dispos. (2000) 28:994-1002.
   PubMed Web of Science ®Google Scholar
• EKINS S, BRAVI G, BINKLEY S etal.: Three- and four-dimensional-quantitative structureactivity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics (1999) 9:477-489.
   PubMedGoogle Scholar
• LOCUSON CW, WAHLSTROM JL: Three-dimensional quantitative structureactivity relationship analysisof cytochromes P450: effect of incorporating higher-affinity ligands and potential new applications. Drug Metab. Dispos. (2005) 33:873-878.
   PubMed Web of Science ®Google Scholar
• KORHNEN LE, RAHNASTO M, MAHONEN NJ: Predictive three-dimensional quantitative structureactivity relationship of cytochrome P450 1A2 inhibitors. J. Med. Chem. (2005) 48:3808-3815.
   PubMed Web of Science ®Google Scholar
• HAJI-MOMENIAN S, RIEGER JM, MACDONALD TL, BROWN ML: Comparative molecular field analysis and QSAR on substrates binding to cytochrome P450 2D6. Bioorg. Med. Chem. (2003) 11:5545-5554.
   PubMed Web of Science ®Google Scholar
• SHARMA V, DUFFEL MW: A comparative molecular field analysis-based approach to prediction of sulfotransferase catalytic specificity. Phase II Conjugation Enz. Transport Sys. (2005) 400:249-270.
   Google Scholar
• BUJNICKI JM: Proteinstructure prediction by recombination of fragments. Chembiochem (2006) 7:19-27.
   PubMed Web of Science ®Google Scholar
• LEWIS DFV, ITO Y, GOLDFARB PS: Cytochrome P450 structures and their substrate interactions. Drug Devel. Res. (2005) 66:19-24.
   Web of Science ®Google Scholar
• ZAMORA I, AFZELIUS L, CRUCIANIG: Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. J. Med. Chem. (2003) 46:2313-2324.
   PubMed Web of Science ®Google Scholar
• KEMP CA, FLANAGAN JU, VAN ELDIK AJ etal.: Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. J. Med. Chem. (2004) 47:5340-5346.
   PubMed Web of Science ®Google Scholar
• COMBES RD, RODFORD RA: The use of expert systems for toxicity prediction: illustration with reference to the DEREK system. In: Predicting Chemical Toxicity and Fate. MTD Cronin, DJ Livingstone (Eds), CRC Press, Boca Raton, FL, USA (2004):193-204.
   Google Scholar
• COECKE S, AHR H, BLAAUBOER BJ etal.: Metabolism: a bottleneck in invitro toxicological test development. The report and recommendations of ECVAM Workshop 54. Altern. Lab. Anim. (2006) 34:49-84.
   PubMed Web of Science ®Google Scholar
• BOOBIS A, GUNDERT-REMY U, KREMERS P, MACHERAS P, PELKONEN O: In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. Eur. J. Pharm. Sci. (2002) 17:183-193.
   PubMed Web of Science ®Google Scholar
• BANIK GM: In silico ADME-Tox prediction: the more the merrier. Curr. Drug. Disc. (2004):31-34.
   Google Scholar
• KLOPMAN G, DIMAYUGA M, TALAFOUS J: META I. A program for the evaluation of metabolic transformation of chemicals. J. Chem. Inf. Comput. Sci. (1994) 34:1320-1325.
   PubMedGoogle Scholar
• KLOPMAN G, TU M, TALAFOUS J: META 3. A genetic algorithm for metabolic transform priorities optimization. J. Chem. Inf. Comput. Sci. (1997) 37:329-334.
   PubMedGoogle Scholar
• TALAFOUS J, SAYRE LM, MIEYAL JJ, KLOPMAN G: META 2. A dictionary model of mammalian xenobiotic metabolism. J. Chem. Inf. Comput. Sci. (1994) 34:1326-1333.
   PubMedGoogle Scholar
• DARVAS F: MetabolExpert, an expert system for predicting metabolism of substances. In: QSAR in Environmental Toxicology. KLE Kaiser (Ed.), Reidel, Dordrecht, The Netherlands (1987):71-81.
   Google Scholar
• DARVAS F: Predicting metabolic pathways by logic programming. J. Mol. Graph. (1988) 6:80-86.
   Google Scholar
• BUTTON WG, JUDSON PN, LONG A, VESSEY JD: Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. J. Chem. Inf. Comp. Sci. (2003) 43:1371-1377.
   PubMedGoogle Scholar
• GREENE N, JUDSON PN, LANGOWSKI JJ, MARCHANT CA: Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ. Res. (1999) 10:299-314.
   PubMed Web of Science ®Google Scholar
• TESTA B, BALMAT AL, LONG A, JUDSON P: Predicting drug metabolism an evaluation of the expert system METEOR. Chem. Biodivers. (2005) 2:872-885.
   PubMed Web of Science ®Google Scholar
• CRUCIANI G, CAROSATI E, DE BOECK B etal.: MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem. (2005) 48:6970-6979.
   PubMed Web of Science ®Google Scholar
• EKINS S, KIRILLOV E, RAKHMATULIN EA, NIKOLSKAYA T: A novel method for visualizing nuclear hormone receptor networks relevant to drug metabolism. Drug Metab. Dispos. (2005) 33:474-481.
   PubMed Web of Science ®Google Scholar
• EKINS S, ANDREYEV S, RYABOV A etal.: Computational prediction of human drug metabolism. Expert Opin. Drug Metab. Toxicol. (2005) 1:303-324.
   PubMed Web of Science ®Google Scholar
• EKINS S, ANDREYEV S, RYABOV A etal.: A combined approach to drug metabolism and toxicity assessment. Drug Metab. Dispos. (2006) 34:495-503.
   PubMed Web of Science ®Google Scholar
• MEKENYAN OG, DIMITROV SD, PAVLOV TS, VEITH GD: A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr. Pharm. Des. (2004) 10:1273-1293.
   PubMed Web of Science ®Google Scholar
• MEKENYAN O, DIMITROV S, DIMITROV N etal.: Metabolic activation of chemicals: in silico simulation. SAR QSAR Environ. Res. (2006) 17:107-120.
   PubMed Web of Science ®Google Scholar
• CALDWELL GW, YAN ZY: Screening for reactive intermediates and toxicity assessment in drug discovery. Curr. Opin Drug Disc. Devel. (2006) 9:47-60.
   PubMed Web of Science ®Google Scholar
• BUGRIM A, NIKOLSKAYA T, NIKOLSKY Y: Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Disc. Today (2004) 9:127-135.
   PubMed Web of Science ®Google Scholar

Websites

• http://mdl.com/products/predictive/metabolite/index.jsp MDL Metabolite Homepage (2006).
   Google Scholar
• http://www.accelrys.com/products/chem_databases/databases/metabolism.html Accelrys Metabolism Homepage (2006).
   Google Scholar
• http://www.accelrys.com/products/catalyst/ Catalyst Home Page (2006).
   Google Scholar
• http://www.tripos.com/index.php?family=modules,SimplePage,&page=sybyl_qsar_with_comfa&s=0 QSAR with CoMFA (2006).
   Google Scholar
• http://www.knowitall.com
   Google Scholar
• http://www.multicase.com/products/prod051.htm
   Google Scholar
• http://www.compudrug.com/
   Google Scholar
• http://www.lhasalimited.org/index.php?cat = 2&sub_cat = 68#
   Google Scholar
• http://www.moldiscovery.com/soft_metasite.php
   Google Scholar
• http://www.genego.com/about/products.shtml#metadrug
   Google Scholar
• http://www.oasis-lmc.org/?section=software&swid=4
   Google Scholar